Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc. also conducting a Phase III study in MBC, which is known as CONTESSA. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180
Debt
Debt-to-Equity RatioN/A
Current Ratio20.52
Quick Ratio20.52
Price-To-Earnings
Trailing P/E Ratio-11.26
Forward P/E Ratio-7.88
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.29 per share
Price / Book3.57
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees60
Outstanding Shares26,890,000
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) issued its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.
What price target have analysts set for ODT?
3 equities research analysts have issued 1 year price objectives for Odonate Therapeutics' stock. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' stock price to reach $33.50 in the next year. View Analyst Ratings for Odonate Therapeutics.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS), Xencor (XNCR), Corcept Therapeutics (CORT), Enanta Pharmaceuticals (ENTA) and TESARO (TSRO).
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 51)
- Mr. John G. Lemkey, Chief Financial Officer (Age 37)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 42)
- Ms. Nicole H. Gollaher J.D., VP of Legal Affairs (Age 49)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 64)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.
When did the company's lock-up period expire?
Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its initial public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has Odonate Therapeutics been receiving favorable news coverage?
Media coverage about ODT stock has trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Odonate Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 45.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (46.16%), Sabby Management LLC (2.73%), Redmile Group LLC (2.21%), Rock Springs Capital Management LP (1.43%), BlackRock Inc. (1.06%) and Victory Capital Management Inc. (0.30%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which major investors are selling Odonate Therapeutics stock?
Which major investors are buying Odonate Therapeutics stock?
ODT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Tang Capital Management LLC, Northern Trust Corp, Schwab Charles Investment Management Inc., California State Teachers Retirement System and The Manufacturers Life Insurance Company . Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $26.00.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $713.07 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
